Motor Weakness - We Can Make a Difference

Motor weakness is a debilitating symptom shared across numerous neuromuscular and neurodegenerative conditions, often profoundly affecting patients’ independence and quality of life. This CME/CE course titled "Motor Weakness – We Can Make a Difference" offers an in-depth exploration of diagnostic advancements, therapeutic interventions, and supportive care approaches for patients with motor weakness, with a strong focus on cutting-edge innovations that are reshaping clinical practice.

Participants will begin by reviewing improvements in pediatric and adult care, including early diagnosis through advanced imaging, electromyography (EMG), and genetic testing. Emphasis is placed on recognizing early signs of neuromuscular disorders and initiating timely referrals for subspecialty evaluation.

A central focus of the course is Spinal Muscular Atrophy (SMA), a leading genetic cause of infant mortality, and the revolutionary progress in its management. Learners will examine the evolution of SMA treatment—from supportive therapies and ventilation management to the advent of disease-modifying drugs and gene replacement therapy, including onasemnogene abeparvovec (Zolgensma), nusinersen (Spinraza), and risdiplam (Evrysdi).

Participants will also explore advancements in adaptive equipment and assistive technologies that empower patients with motor deficits to achieve greater functional autonomy. Topics include powered mobility devices, robotic exoskeletons, augmentative communication tools, and customized orthotics. These innovations are discussed within the context of interdisciplinary rehabilitation strategies.

The course integrates real-world patient cases, ethical considerations around cost and access to genetic therapies, and the importance of patient-centered supportive care—spanning physical therapy, nutrition, respiratory support, and psychosocial services.

By the end of the program, clinicians will have the tools to assess emerging therapeutic modalities, balance risks and benefits, and deliver evidence-based care that improves both survival and quality of life for individuals living with motor weakness.

Educational Objectives

• Understand advancements in motor weakness diagnosis, pediatric care, and supportive interventions.
• Explore the role of adaptive equipment in enhancing mobility and independence.
• Analyze the genetic etiology of Spinal Muscular Atrophy and the trajectory of its treatment evolution.
• Evaluate current and emerging disease-targeted therapies, including gene replacement technologies.
• Discuss the clinical, ethical, and practical implications of innovative treatments in improving patient-centered outcomes.

Who Should Do This Course?

This course is ideal for:

• Pediatric Neurologists, Neurologists, and Neurosurgeons managing neuromuscular disorders.
• Physical Medicine and Rehabilitation physicians developing personalized rehab strategies.
• Occupational Medicine and Orthopedic Surgery professionals involved in mobility and adaptive device care.
• Nurse Practitioners and Physician Assistants working in multidisciplinary neurology or rehabilitation clinics.
• Primary Care, Family Medicine, and Internal Medicine providers monitoring long-term disability care plans.

It is also beneficial for Geriatricians treating age-related motor decline and allied health professionals supporting rehabilitation.

Did You Know?

• Spinal Muscular Atrophy affects 1 in 10,000 live births and is a leading genetic cause of death in infancy. (NIH, 2023)
• Gene therapy for SMA has shown survival benefit when delivered early, ideally before symptom onset. (New England Journal of Medicine, 2021)
• Robotic exoskeletons are now FDA-cleared to assist individuals with lower limb weakness in walking. (FDA, 2022)
• Adaptive mobility equipment can reduce caregiver burden by 40% and increase patient participation in school or work. (Archives of Physical Medicine and Rehabilitation, 2022)
• Motor weakness contributes to up to 25% of pediatric neurologic consults in tertiary care centers. (Pediatrics, 2021)